IL7 and glioblastoma: IL7 expressing CAR T cells improved overall survival in mice pre-treated with a non-lymphodepleting dose of irradiation – allowing for retention of host immune cells – thus, the use of IL7 expressing CAR T cells can open opportunities for combinations of other immunotherapies in glioblastoma.